This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Loser

Vertex Pharmaceuticals ( VRTX) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.9%. By the end of trading, Vertex Pharmaceuticals fell $1.15 (-2.1%) to $52.40 on light volume. Throughout the day, two million shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 4.2 million shares. The stock ranged in price between $51.56-$53.71 after having opened the day at $52.65 as compared to the previous trading day's close of $53.55. Other company's within the Drugs industry that declined today were: Allos Therapeutics ( ALTH), down 20.1%, K-V Pharmaceutical Company ( KV.A), down 12.3%, Cormedix ( CRMD), down 11.9%, and Amyris ( AMRS), down 11%.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Vertex Pharmaceuticals has a market cap of $11.17 billion and is part of the health care sector. The company has a P/E ratio of 36.5, below the average drugs industry P/E ratio of 38.6 and above the S&P 500 P/E ratio of 17.7. Shares are up 59.4% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Anthera Pharmaceuticals ( ANTH), up 87.2%, Alnylam Pharmaceuticals ( ALNY), up 53%, Par Pharmaceutical Companies ( PRX), up 36.7%, and iBio ( IBIO), up 31.3%, were all gainers within the drugs industry with Sanofi ( SNY) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!
DOW 16,566.58 +166.91 1.02%
S&P 500 1,931.99 +27.98 1.47%
NASDAQ 4,389.4430 +73.3690 1.70%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs